ClinicalTrials.Veeva

Menu

NKI Therapy Compared to Usual Care of Recurrent Esophagogastric Anastomotic Strictures (SAMURAI)

R

Radboud University Medical Center

Status

Terminated

Conditions

Esophageal Stricture
Dilation of Esophagus Due to Disease
Anastomotic Stenosis

Treatments

Procedure: NKI followed by EBD

Study type

Interventional

Funder types

Other

Identifiers

NCT04406428
NL65652.091.18

Details and patient eligibility

About

Rationale: The study hypothesizes that NKI followed by endoscopic bougie dilation therapy will result in an increased dysphagia-free period, a reduction of endoscopic procedures and dysphagia-related quality of life, and lower costs, when compared with the standard endoscopic bougie dilation (EBD) in recurrent esophagogastric anastomotic strictures.

Objective: To evaluate the efficacy and cost-effectiveness of needle-knife incision (NKI) followed by EBD compared to standard EBD in patients with recurrent esophagogastric anastomotic strictures.

Study design: This multicenter study is an randomized controlled trial in which NKI followed by EBD will be compared with standard EBD.

Study population: Patients with recurrent dysphagia (at least 1 and a maximum of 5 previous dilations) due to an anastomotic esophagogastric stricture that requires treatment with repeated endoscopic bougie dilations.

Intervention : The intervention to be investigated is the addition of NKI therapy to EBD to 18 mm esophageal diameter.

Main study parameters/endpoints: The primary outcome of this study will be EBD-free time during follow-up of 6 months. Secondary outcome parameters will be the number of endoscopic procedures for treatment of dysphagia, quality of life (QoL), cost-reduction and cost-effectiveness.

Enrollment

15 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Recurrent intra- or extrathoracic benign esophagogastric anastomotic stricture after esophagectomy. The definition of a stricture is based on the Ogilvie Dysphagia score (severity of dysphagia), i.e. Ogilvie score ≥2 (= ability to swallow semi-solid food or worse (Appendix table 1)).
  • No patency for a standard endoscope (diameter < 10 mm)
  • The recurrent stricture has been previously treated with at least 1 to a maximum of 5 EBD sessions that reached an esophageal diameter of ≥16 mm.
  • The stricture should be suitable for endoscopic incision (stricture length ≤10 mm).

Exclusion criteria

  • Benign esophageal stricture other than an esophagogastric anastomotic stricture.
  • Strictures with a morphology unsuitable for NKI, such as long (>1 cm), irregulair or tortuous strictures.
  • Previous endoscopic treatment of the esophageal stricture with steroid injection, incision therapy or stent placement within the past 3 months.
  • Previous stent placement post-esophagectomy for anastomotic leakage.
  • (Suspicion of) locally recurrent or metastasized esophageal cancer.
  • Persisting postoperative esophageal fistula.
  • Inability to discontinue anticoagulants or high-dose antiplatelet drugs at time of the baseline procedure. Low-dose aspirin (max. 100 mg/day) may be continued.
  • Known clotting disorder that cannot pre-procedural be corrected.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

15 participants in 2 patient groups

NKI followed by EBD
Experimental group
Treatment:
Procedure: NKI followed by EBD
Standard EBD
No Intervention group

Trial contacts and locations

1

Loading...

Central trial contact

Lieke Koggel, Drs.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems